Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Breast Cancer

  Free Subscription

Articles published in Ann Oncol

Retrieve available abstracts of 67 articles:
HTML format

Single Articles

    January 2022
  1. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Corrigendum to "Bringing safe and effective therapies to premenopausal women with breast cancer: efforts to broaden eligibility criteria": [Annals of Oncology 32 (2021) 950-953].
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(22)00002.

  2. NITZ UA, Gluz O, Christgen M, Grischke EM, et al
    Corrigendum to "De-escalation strategies in HER2-positive early breast cancer (EBC): final analysis of the WSG-ADAPT HER2+/HR- phase II trial: efficacy, safety, and predictive markers for 12weeks of neoadjuvant dual blockade with trastuzumab and pertu
    Ann Oncol. 2022 Jan 7. pii: S0923-7534(21)04883.

    December 2021
  3. CURIGLIANO G, Mueller V, Borges V, Hamilton E, et al
    Tucatinib vs Placebo Added to Trastuzumab and Capecitabine for Patients with Pretreated HER2+ Metastatic Breast Cancer with and without Brain Metastases (HER2CLIMB): Final Overall Survival Analysis.
    Ann Oncol. 2021 Dec 22. pii: S0923-7534(21)04879.
    PubMed     Abstract available

  4. TARANTINO P, Burstein HJ, Lin NU, Krop IE, et al
    Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib?
    Ann Oncol. 2021 Dec 20. pii: S0923-7534(21)04877.

  5. SPRING L, Matikas A, Bardia A, Foukakis T, et al
    Adjuvant abemaciclib for high-risk breast cancer: the story continues.
    Ann Oncol. 2021;32:1457-1459.

    November 2021
  6. CARDOZO JMNL, Byng D, Drukker CA, Schmidt MK, et al
    Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04829.
    PubMed     Abstract available

  7. POGGIO F, Tagliamento M, Ceppi M, Bruzzone M, et al
    Adding a platinum agent to neoadjuvant chemotherapy for triple negative breast cancer: the end of the debate.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04831.

  8. HAN HS, Arun BK, Kaufman B, Wildiers H, et al
    Veliparib monotherapy following carboplatin/paclitaxel plus veliparib combination therapy in patients with germline BRCA-associated advanced breast cancer: results of exploratory analyses from the phase III BROCADE3 trial.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04833.
    PubMed     Abstract available

  9. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; 32: 983-993.
    Ann Oncol. 2021 Nov 2. pii: S0923-7534(21)04520.

    October 2021
  10. HARBECK N, Rastogi P, Shahir A, Johnston S, et al
    Letter to the Editor for "Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study".
    Ann Oncol. 2021 Oct 28. pii: S0923-7534(21)04551.

    PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later.
    Ann Oncol. 2021 Oct 19. pii: S0923-7534(21)04523.

  12. GENNARI A, Andre F, Barrios CH, Cortes J, et al
    ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.
    Ann Oncol. 2021 Oct 13. pii: S0923-7534(21)04498.

  13. HE W, Eriksson M, Eliasson E, Grassmann F, et al
    CYP2D6 genotype predicts tamoxifen discontinuation and drug response: a secondary analysis of the KARISMA trial.
    Ann Oncol. 2021;32:1286-1293.
    PubMed     Abstract available

    September 2021
  14. HARBECK N, Rastogi P, Martin M, Tolaney SM, et al
    Adjuvant Abemaciclib Combined With Endocrine Therapy for High-Risk Early Breast Cancer: Updated Efficacy and Ki-67 Analysis From the monarchE Study.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04494.
    PubMed     Abstract available

  15. WANG Y, Acs B, Robertson S, Liu B, et al
    Improved breast cancer histological grading using deep learning.
    Ann Oncol. 2021 Sep 29. pii: S0923-7534(21)04486.
    PubMed     Abstract available

  16. LLOP-GUEVARA A, Loibl S, Villacampa G, Vladimirova V, et al
    Association of RAD51 with Homologous Recombination Deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial.
    Ann Oncol. 2021 Sep 11. pii: S0923-7534(21)04478.
    PubMed     Abstract available

  17. HODGSON D, Lai Z, Dearden S, Barrett JC, et al
    Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
    Ann Oncol. 2021 Sep 6. pii: S0923-7534(21)04458.
    PubMed     Abstract available

    August 2021
  18. SALGADO R, Peg V, Ruschoff J, Vincent-Salomon A, et al
    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective.
    Ann Oncol. 2021 Aug 27. pii: S0923-7534(21)04278.

  19. SCHRODI S, Braun M, Andrulat A, Harbeck N, et al
    Outcome of breast cancer patients with low hormone receptor positivity: Analysis of a 15-year population-based cohort.
    Ann Oncol. 2021 Aug 19. pii: S0923-7534(21)04218.
    PubMed     Abstract available

  20. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [An
    Ann Oncol. 2021 Aug 16. pii: S0923-7534(21)02209.

  21. RASSY E, Pistilli B
    Are all taxanes equal in patients with HER2-positive breast cancer? PERUSing the safety and efficacy of trastuzumab plus pertuzumab and taxanes in real-life usual care.
    Ann Oncol. 2021 Aug 14. pii: S0923-7534(21)03980.

  22. JERUSALEM G, Farah S, Courtois A, Chirgwin J, et al
    Continuous vs intermittent extended adjuvant letrozole for breast cancer: Final results of randomized phase 3 SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy.
    Ann Oncol. 2021 Aug 9. pii: S0923-7534(21)02492.
    PubMed     Abstract available

  23. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    Corrigendum to 'First-line atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis': Annals of Oncology 2021; volume 32: 983-993.
    Ann Oncol. 2021 Aug 2. pii: S0923-7534(21)02211.

  24. EMENS LA, Adams S, Barrios CH, Dieras V, et al
    First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.
    Ann Oncol. 2021;32:983-993.
    PubMed     Abstract available

  25. VOORWERK L, Kok M
    'IMpassionate conflicts' in immunotherapy trials for metastatic triple-negative breast cancer.
    Ann Oncol. 2021;32:947-949.

  26. PAGE K, Martinson LJ, Hastings RK, Fernandez-Garcia D, et al
    Prevalence of ctDNA in early screen-detected breast cancers using highly sensitive and specific dual molecular barcoded personalised mutation assays.
    Ann Oncol. 2021;32:1057-1060.

    July 2021
  27. LOI S, Michiels S, Adams S, Loibl S, et al
    The journey of tumor infiltrating lymphocytes (TIL) as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition.
    Ann Oncol. 2021 Jul 23. pii: S0923-7534(21)02185.
    PubMed     Abstract available

  28. BURSTEIN HJ, Curigliano G, Thurlimann B, Weber WP, et al
    CUSTOMIZING LOCAL AND SYSTEMIC THERAPIES FOR WOMEN WITH EARLY BREAST CANCER: The St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.
    Ann Oncol. 2021 Jul 6. pii: S0923-7534(21)02104.
    PubMed     Abstract available

  29. MILES D, Ciruelos E, Schneeweiss A, Puglisi F, et al
    Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication.
    Ann Oncol. 2021 Jul 2. pii: S0923-7534(21)02105.
    PubMed     Abstract available

  30. MILES D, Gligorov J, Andre F, Cameron D, et al
    Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.
    Ann Oncol. 2021 Jul 1. pii: S0923-7534(21)02026.
    PubMed     Abstract available

    June 2021
  31. BARDIA A, Tolaney SM, Punie K, Loirat D, et al
    Biomarker Analyses in the Phase 3 ASCENT Study of Sacituzumab Govitecan Versus Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer.
    Ann Oncol. 2021 Jun 8. pii: S0923-7534(21)02047.
    PubMed     Abstract available

    May 2021
  32. PICCART MJ, Kalinsky K, Gray R, Barlow WE, et al
    Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
    Ann Oncol. 2021 May 31. pii: S0923-7534(21)02029.

    Characteristics of residual invasive breast cancer after neoadjuvant therapy in the KATHERINE study.
    Ann Oncol. 2021 May 28. pii: S0923-7534(21)02027.

  34. SLAMON DJ, Neven P, Chia S, Jerusalem G, et al
    Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase 3 randomized MONALEESA-3 trial: updated overall survival.
    Ann Oncol. 2021 May 15. pii: S0923-7534(21)01553.
    PubMed     Abstract available

  35. GAO JJ, Krol D, Narayan P, Cardoso F, et al
    Bringing Safe and Effective Therapies to Premenopausal Women with Breast Cancer: Efforts to Broaden Eligibility Criteria.
    Ann Oncol. 2021 May 12. pii: S0923-7534(21)01556.

    April 2021
  36. MAMOUNAS EP, Untch M, Mano MS, Huang CS, et al
    Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.
    Ann Oncol. 2021 Apr 28. pii: S0923-7534(21)01168.
    PubMed     Abstract available

    February 2021
  37. DU L, Yau C, Brown-Swigart L, Gould R, et al
    Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer prior to chemo-endocrine therapy.
    Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00128.
    PubMed     Abstract available

  38. AGOSTINETTO E, Ignatiadis M
    Optimal treatment for aromatase inhibitor-resistant metastatic breast cancer patients: Lessons from the PEARL study.
    Ann Oncol. 2021 Feb 8. pii: S0923-7534(21)00106.

  39. BRUFSKY A, Kim SB, Zvirbule Z, Eniu A, et al
    A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis.
    Ann Oncol. 2021 Feb 1. pii: S0923-7534(21)00093.
    PubMed     Abstract available

  40. MATIKAS A, Foukakis T
    SOLAR1s: alpelisib returns to earth?
    Ann Oncol. 2021;32:129-132.

  41. VANACKER H, Cassier PA, Bachelot T
    The complex balance of PI3K inhibition.
    Ann Oncol. 2021;32:127-128.

    January 2021
  42. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.

  43. CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
    Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
    PubMed     Abstract available

  44. DENKERT C, Untch M, Benz S, Schneeweiss A, et al
    Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy.
    Ann Oncol. 2021 Jan 5. pii: S0923-7534(20)43224.
    PubMed     Abstract available

    December 2020
  45. LOHMANN AE, Goodwin PJ
    Diabetes, metformin and breast cancer: a tangled web.
    Ann Oncol. 2020 Dec 31. pii: S0923-7534(20)43222.

  46. MARTIN M, Zielinski C, Ruiz-Borrego M, Carrasco E, et al
    Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL.
    Ann Oncol. 2020 Dec 29. pii: S0923-7534(20)43221.
    PubMed     Abstract available

  47. PARK YM, Bookwalter DB, O'Brien KM, Jackson CL, et al
    A Prospective Study of Type 2 diabetes, metformin use, and risk of breast cancer.
    Ann Oncol. 2020 Dec 19. pii: S0923-7534(20)43214.
    PubMed     Abstract available

  48. FRANZOI MA, Romano E, Piccart M
    Immunotherapy for early breast cancer: too soon, too superficial, or just right?
    Ann Oncol. 2020 Dec 8. pii: S0923-7534(20)43198.
    PubMed     Abstract available

  49. GRINSHPUN A, Moss J, Uziely B
    Key Role for Liquid Biopsy in the Elimination of Breast Cancer Surgery following Neoadjuvant Therapy.
    Ann Oncol. 2020 Dec 7. pii: S0923-7534(20)43201.

  50. AMIRI-KORDESTANI L, Xie D, Tolaney SM, Bloomquist E, et al
    A Food and Drug Administration analysis of survival outcomes comparing the Adjuvant Paclitaxel and Trastuzumab trial with an external control from historical clinical trials.
    Ann Oncol. 2020;31:1704-1708.
    PubMed     Abstract available

    November 2020
  51. ANDRE F, Ciruelos EM, Juric D, Loibl S, et al
    Alpelisib Plus Fulvestrant for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2-Negative Advanced Breast Cancer: Final Overall Survival Results From SOLAR-1.
    Ann Oncol. 2020 Nov 24. pii: S0923-7534(20)43166.
    PubMed     Abstract available

  52. EIKESDAL HP, Yndestad S, Elzawahry A, Llop-Guevara A, et al
    Olaparib Monotherapy as Primary Treatment in Unselected Triple Negative Breast Cancer.
    Ann Oncol. 2020 Nov 23. pii: S0923-7534(20)43164.
    PubMed     Abstract available

  53. MAGBANUA MJM, Swigart LB, Wu HT, Hirst GL, et al
    Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival.
    Ann Oncol. 2020 Nov 21. pii: S0923-7534(20)43162.
    PubMed     Abstract available

  54. XU B, Sun T, Zhang Q, Zhang P, et al
    Efficacy of utidelone plus capecitabine versus capecitabine for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer: final analysis of overall survival in a phase 3 randomised controlled trial.
    Ann Oncol. 2020 Nov 11. pii: S0923-7534(20)43130.
    PubMed     Abstract available

  55. DENT S, Cortes J, Im YH, Dieras V, et al
    Phase III randomized study of taselisib or placebo with fulvestrant in estrogen receptor-positive, PIK3CA-mutant, HER2-negative, advanced breast cancer: the SANDPIPER trial.
    Ann Oncol. 2020 Nov 10. pii: S0923-7534(20)43124.
    PubMed     Abstract available

    PARP inhibition in homologous recombination deficient early stage breast cancer.
    Ann Oncol. 2020 Nov 9. pii: S0923-7534(20)43128.

    October 2020
  57. FASCHING PA, Link T, Hauke J, Seither F, et al
    Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42963.
    PubMed     Abstract available

  58. SIPOS O, Tovey H, Quist J, Haider S, et al
    Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    Ann Oncol. 2020 Oct 21. pii: S0923-7534(20)42977.
    PubMed     Abstract available

  59. STECKLEIN SR, Sharma P
    Last but not Least: Antibody-Drug Conjugates in Hormone Receptor-Positive Metastatic Breast Cancer.
    Ann Oncol. 2020 Oct 7. pii: S0923-7534(20)42492.

  60. LIN NU
    Reevaluating the role of antibody-drug conjugates in the treatment of patients with brain metastases.
    Ann Oncol. 2020;31:1279-1281.

    September 2020
  61. GRINDA T, Delaloge S
    Survival benefits of PARP inhibitors in advanced breast cancer: a mirage?
    Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42468.

  62. CARDOSO F, Paluch-Shimon S, Senkus E, Curigliano G, et al
    5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)(dagger).
    Ann Oncol. 2020 Sep 23. pii: S0923-7534(20)42460.

  63. KALINSKY K, Diamond JR, Vahdat LT, Tolaney SM, et al
    Sacituzumab Govitecan in Previously Treated Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Final Results from a Phase 1/2, Single-Arm, Basket Trial.
    Ann Oncol. 2020 Sep 15. pii: S0923-7534(20)42445.
    PubMed     Abstract available

  64. KARN T, Denkert C, Weber KE, Holtrich U, et al
    Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GeparNuevo.
    Ann Oncol. 2020;31:1216-1222.
    PubMed     Abstract available

    May 2020
  65. CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
    European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
    Ann Oncol. 2020;31:650-658.
    PubMed     Abstract available

    March 2020
  66. YVER A, Agatsuma T, Soria JC
    The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.
    Ann Oncol. 2020;31:430-434.

  67. KURZROCK R, Bowles DW, Kang H, Meric-Bernstam F, et al
    Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study.
    Ann Oncol. 2020;31:412-421.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.